AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06278792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diuretic protocol
Description: Nurse-led natriuresis-guided protocol based on a bedside urinary sodium result
Study NCT06278792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Diuretic therapy at the discretion of the physician
Study NCT04816474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education and Phone Counseling Service
Description: Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
Study NCT05177614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Upper-level multiple micronutrient-fortified bouillon cube
Description: 80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
Study NCT05177614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lower-level multiple micronutrient-fortified bouillon cube
Description: 28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
Study NCT05177614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iodine-fortified bouillon cube
Description: 30 µg/g Iodine (KIO3)
Study NCT04498715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OSTEOSYNTHESIS
Description: Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
Study NCT04498715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OSTEOSYNTHESIS
Description: Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
Study NCT04498715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
Study NCT04498715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
Study NCT04498715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERAMENT BONE VOID FILLER (BVF)
Description: CERAMENT™\|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™\|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw.
Study NCT05889715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Wellness Program: Plants-2-Plate
Description: A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
Study NCT06543901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submuscular plating
Description: the patient was fixed with a submuscular plate
Study NCT06543901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traction and casting
Description: the patient was placed on a traction with a thomas splint and then was casted with a hip spica
Study NCT04842097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
Study NCT05003427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04
Description: 68Ga-FAPI-04 were injected into the patients before the PET/CT scans
Study NCT05754853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRG002
Description: Administrated intravenously
Study NCT05754853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injection
Description: Administrated intravenously
Study NCT05754853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: Administrated intravenously
Study NCT05754853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride for Injection
Description: Administrated intravenously
Study NCT05754853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium Injection
Description: Administrated intravenously
Study NCT06040411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
Study NCT06079385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Acupuncture treatment with needles
Study NCT06462053 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Short-course radiotherapy: 25Gy/5Fx
Study NCT06462053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody (Toripalimab)
Description: Toripalimab 240mg d1 q3w
Study NCT06462053 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long-course radiotherapy
Description: Long-course radiation: 50Gy/25Fx
Study NCT06462053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study NCT06462053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Xeloda
Study NCT05110768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic AVNU
Description: Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy
Study NCT05110768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal TPN solution without FPC on alternate days with TPN supplemented with multivitamins.
Study NCT04300075 — intervention group
Intervention type: DEVICE
Intervention: CUSABT
Description: Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
Study NCT03438500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)
Description: 40 - 60 spots per visit (200 shots/spot) at Energy Level 3
Study NCT05790330 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: As per usual standard of care
Study NCT05790330 — intervention group
Intervention type: DRUG
Intervention: Dupilumab
Description: As per usual standard of care
Study NCT05408832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Trial ABCCBA
Description: Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.
Study NCT05408832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Trial CBAABC
Description: Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.
Study NCT05408832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Techniques with No Randomization Sequence (or order)
Description: Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
Study NCT04849351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-689
Description: All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
Study NCT06416709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times
Study NCT06416709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 10 ml saline is used as placebo once every three days and for three times
Study NCT05998161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reviga
Description: Participants will receive access to the digital health intervention reviga in addition to TAU.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurement
Description: The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurement
Description: The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurement
Description: The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurement
Description: The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vibration-controlled transient elastography (VCTE) attenuation measurement
Description: The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration-controlled transient elastography (VCTE) attenuation measurement
Description: The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vibration-controlled transient elastography (VCTE) stiffness measurement
Description: The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration-controlled transient elastography (VCTE) stiffness measurement
Description: The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) stiffness measurement
Description: EUS-SWE will be performed by an experienced endoscopist, blinded to clinical records. The expert will use the ArrietaTM 850 EUS console (Fujifilm, Tokyo, Japan) using a linear ultrasound video gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). Both lobes will be evaluated. The transducer will be positioned in the gastric window to visualize right liver segment number five and left liver segment two or three. The elastogram region of interest (ROI) will be placed within the liver tissue at a distance ≥10 mm beneath the hepatic capsule in an area free of vessels and artefacts. A 10-mm circular ROI will be placed within the elastogram at a depth of 4-5 cm from the skin, and a minimum of ten successful kilopascal measurements will be obtained.~In the first stage of this research, the EUS-SWE measurement will be limited to the estimation of liver fibrosis only. Currently, available EUS-SWE equipment does not allow the estimation of the attenuation.
Study NCT06102980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) stiffness measurement
Description: EUS-SWE will be performed by an experienced endoscopist, blinded to clinical records. The expert will use the ArrietaTM 850 EUS console (Fujifilm, Tokyo, Japan) using a linear ultrasound video gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). Both lobes will be evaluated. The transducer will be positioned in the gastric window to visualize right liver segment number five and left liver segment two or three. The elastogram region of interest (ROI) will be placed within the liver tissue at a distance ≥10 mm beneath the hepatic capsule in an area free of vessels and artefacts. A 10-mm circular ROI will be placed within the elastogram at a depth of 4-5 cm from the skin, and a minimum of ten successful kilopascal measurements will be obtained.~In the first stage of this research, the EUS-SWE measurement will be limited to the estimation of liver fibrosis only. Currently, available EUS-SWE equipment does not allow the estimation of the attenuation.
Study NCT05571345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: PF614 capsules (50 mg or 100 mg)
Study NCT05571345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Hydrochloride 40 mg
Description: Oral 20 mg tablets (two each)
Study NCT05571345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF614 capsules will be provided by the sponsor.
Study NCT05569772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector
Description: maintenance dose of 1mg SC once weekly
Study NCT05569772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo
Description: maintenance dose of 1mg SC once weekly
Study NCT05786495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Discontinuation of Antibiotics
Description: Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count
Study NCT05786495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
Study NCT05538559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal by Carie-Care
Description: caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.
Study NCT05538559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical caries removal by Atraumatic Restorative Technique
Description: caries in primary teeth will be removed using the mechanical caries removal by ART method.
Study NCT05614986 — intervention group
Intervention type: OTHER
Intervention: 5 minute Montreal Cognitive Assessment (mini MoCA)
Description: The mini MoCA will be completed by the patient before TAVR, and 30 days and 6 months after TAVR
Study NCT04485858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorNeat KPro
Description: CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
Study NCT05195229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVID-19 Aerosol Collection
Description: Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator.
Study NCT06594783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol plus endoscopic variceal ligation
Description: Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
Study NCT06594783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol alone
Description: Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).